Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

147 results about "Gastrointestinal cancer" patented technology

Gastrointestinal cancer refers to malignant conditions of the gastrointestinal tract (GI tract) and accessory organs of digestion, including the esophagus, stomach, biliary system, pancreas, small intestine, large intestine, rectum and anus. The symptoms relate to the organ affected and can include obstruction (leading to difficulty swallowing or defecating), abnormal bleeding or other associated problems. The diagnosis often requires endoscopy, followed by biopsy of suspicious tissue. The treatment depends on the location of the tumor, as well as the type of cancer cell and whether it has invaded other tissues or spread elsewhere. These factors also determine the prognosis.

Culture medium of hericium erinaceus, bio-converted mycelium, extract of the bio-converted mycelium, and application of the extract

The invention discloses a culture medium of hericium erinaceus, a bio-converted mycelium, an extract of the bio-converted mycelium, and an application of the extract. The culture medium is prepared by adding a traditional Chinese medicine, sculellaria barbata, to a base culture medium and includes the base culture medium and the sculellaria barbata. 100 parts of the culture medium includes 50-70 parts of the base culture medium and 30-50 parts of the sculellaria barbata, wherein the base culture medium includes, by weight, 350-490 parts of wheat bran, 100-140 parts of corn flour, 45-63 parts of grain bran, 5-7 parts of white sugar and 400-600 parts of water. The bio-converted mycelium is a product that is prepared by inoculating the hericium erinaceus on the culture medium through mycelium conversion. The extract of the bio-converted mycelium is prepared by water-extracting and then pressure-reduced-concentrating the hericium erinaceus mycelium and finally performing vacuum freeze-drying. The extract of the bio-converted mycelium has the effect of resisting gastrointestinal cancer, wherein the effect is significantly better than that of the hericium erinaceus mycelium and the sculellaria barbata independently, so that the extract can be used for preparing an anti-gastrointestinal cancer medicine.
Owner:HUNAN XINHUI PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products